Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Pharnext SCA
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharnext SCA
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Pharnext SCA
OTC:PNEXF
Additional Paid In Capital
€15.1m
CAGR 3-Years
-49%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Additional Paid In Capital
€593.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Additional Paid In Capital
€446.5m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
17%
Inventiva SA
PAR:IVA
Additional Paid In Capital
€201.9m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Additional Paid In Capital
€33.6m
CAGR 3-Years
-6%
CAGR 5-Years
-26%
CAGR 10-Years
-12%
OSE Immunotherapeutics SA
PAR:OSE
Additional Paid In Capital
€76.8m
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
N/A
No Stocks Found

Pharnext SCA
Glance View

Market Cap
6T USD
Industry
Biotechnology

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

PNEXF Intrinsic Value
Not Available

See Also

What is Pharnext SCA's Additional Paid In Capital?
Additional Paid In Capital
15.1m EUR

Based on the financial report for Jun 30, 2023, Pharnext SCA's Additional Paid In Capital amounts to 15.1m EUR.

What is Pharnext SCA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
-23%

Over the last year, the Additional Paid In Capital growth was 6%. The average annual Additional Paid In Capital growth rates for Pharnext SCA have been -49% over the past three years , -23% over the past five years .

Back to Top